{
    "Trade/Device Name(s)": [
        "Idylla MSI Test"
    ],
    "Submitter Information": "Biocartis NV",
    "510(k) Number": "K211181",
    "Predicate Device Reference 510(k) Number(s)": [
        "K200129"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PZJ"
    ],
    "Summary Letter Date": "October 21, 2022",
    "Summary Letter Received Date": "October 21, 2022",
    "Submission Date": "February 27, 2023",
    "Regulation Number(s)": [
        "21 CFR 864.1866"
    ],
    "Regulation Name(s)": [
        "Lynch syndrome test systems"
    ],
    "Analyte Class(es)": [
        "genetic molecular",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "ACVR2A",
        "BTBD7",
        "DIDO1",
        "MRE11",
        "RYR3",
        "SEC31A",
        "SULF2"
    ],
    "Specimen Type(s)": [
        "Formalin-fixed, paraffin-embedded (FFPE) colorectal tumor tissue sections"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Idylla System"
    ],
    "Method(s)/Technology(ies)": [
        "PCR amplification",
        "High-resolution melting analysis",
        "Fluorescent molecular beacon detection"
    ],
    "Methodologies": [
        "PCR-based microsatellite instability analysis",
        "Qualitative genetic testing"
    ],
    "Submission Type(s)": [
        "Test",
        "Assay",
        "Cartridge",
        "Reagent",
        "System",
        "Software"
    ],
    "Document Summary": "FDA 510(k) summary for Biocartis Idylla MSI Test using PCR-based MSI detection on FFPE colorectal cancer tissue as an aid for Lynch syndrome screening.",
    "Indications for Use Summary": "For qualitative identification of microsatellite instability (MSI) in colorectal cancer tumors, indicative of mismatch repair deficiency, to aid in identifying patients for additional genetic testing for Lynch syndrome; not for diagnosis of colorectal cancer.",
    "fda_folder": "Immunology"
}